360 results about "Uremia" patented technology

A portable peritoneal dialysis system for a patient includes an inlet port for providing inflow to the patient's peritoneal cavity, an outlet port for providing outflow from the patient's peritoneal cavity, and a volume of dialysate for flow into and out of the patient's peritoneal cavity, thereby removing from the dialysate uremic waste metabolites that have diffused into the dialysate. The portable peritoneal dialysis system also includes a closed liquid flow loop, including a pump, for flowing the dialysate into and out of the patient's peritoneal cavity, and an organic- and phosphate-removing stage, including at least one replaceable cartridge in the closed liquid flow loop, the cartridge containing material for removing organic compounds and phosphate from dialysate removed from the patient's peritoneal cavity. The portable peritoneal dialysis system further includes a urea- and ammonia-removing stage, including at least one replaceable cartridge in the closed liquid flow loop, the cartridge containing material for removing urea and ammonia from dialysate removed from the patient's peritoneal cavity, the material being packed around semi-permeable hollow fibers with interior fiber walls that reject cations, thereby retaining cations in the dialysate.

The present disclosure relates to a wearable dialysis system and method for removing uremic waste metabolites and fluid from a patient suffering from renal disease. Uremic waste metabolites can be removed by a wearable peritoneal dialysis device that regenerates the peritoneal dialysis solution without removing positively charged, essential ions from the solution and, consequently, the patient. Fluids can be removed from the blood of the patient by an implantable fluid removing device. Fluids are delivered to the bladder and preferably removed from the body of the patient through urination. The wearable dialysis system may be operated continuously or semi-continuously and be comfortably adapted to the body of the patient while allowing the patient to perform normal activities.

The invention provides a traditional Chinese medicine composition for treating complication of uremia caused by hematodialysis, which comprises astragalus, dangshen, Chinese yam, semen coicis, carthamus tinctorius, frangula emodin, herba orostachyos, dendrobe, arillus longan, dandelion, angelica sinensis, fructus kochiae, kelp, motherwort, radix salviae miltiorrhizae, pokeberry root, morinda officinalis, trametes versicolor, fructus psoraleae and acanthopanax root. The traditional Chinese medicine composition can well treat the complication such as skin itch and malnutrition caused by hematodialysis, and has the advantages of being high in treatment effect, short in course of treatment and rapid in taking effect when being used for treating the uremia by being matched with hematodialysis.

The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.

A health-care sugar cane juice beverage for preventing nephritis, renal failure and uremia, and treating cough and bronchitis is prepared from sugar can juice and 16 Chinese-medicinal materials including wolfberry fruit, honeysuckle flower, liquorice root, scutellaria root, etc.

The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. The oral delivery composition may be able to deliver the uremic toxin-treating enzymes, substantially undigested, to the intestines, where the enzymes can interact with uremic toxins transported to the intestines from the bloodstream. In another aspect, the treatment includes an oral delivery composition comprising a cell able to reduce the concentration of one or more uremic toxins in vivo. In some cases, the cell may be designed to overexpress one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase, for example, by transfecting the cell with a corresponding gene. In some embodiments, a species able to react with or otherwise sequester by-products of the uremic toxin-treating enzyme reactions may be included with the oral delivery composition. For example, if the by-product is ammonium, the species may be a sorbent able to adsorb ammonium, an enzyme able to react with the ammonium, or the like.

The invention relates to an adsorbent used for clearing middle and macro molecule toxin in body of uremia patients and a preparation method thereof. According to the molecule size of middle and macromolecules such as beta2-MG, PTH, AGEs, Hcy and IL-6 and performance characteristics thereof, a functional adsorbent which can efficiently clear main middle and macro molecule toxins such as beta2-MG,PTH, AGEs, Hcy and IL-6 in the blood of the uremia patients is prepared by taking a mesoporous polystyrene hydrophobic resin as a carrier, which undergoes chloromethylation activation, and then performing chemical crosslinking grafting of vinylamine; and the adsorbent has large adsorption capacity, good mechanical strength, good biocompatibility and high adsorption selectivity. The adsorbent is used for treating uremia by blood perfusion, can take the advantages of blood filtering mainly for clearing micromolecular toxin, and provides a new method for treating uremia by combination of hematodialysis and blood perfusion.

The invention relates to a blood purification adsorbent for uremia and a preparation method of the adsorbent. The blood purification adsorbent is carbon nanotube/nano silica/polystyrene resin composite microspheres, carbon nanotubes and nano silica are dispersed in polystyrene resin, and the polystyrene resin adopts a porous crosslinked structure. The preparation method comprises the steps of suspension polymerization, a chloromethylation reaction, post-crosslinking and surface modification. The provided and prepared blood purification adsorbent has high strength, adsorptive property and adsorption efficiency, has better adsorptive performance for special toxins and is particularly applicable to blood perfusion for uremia.

The present invention discloses one kind of Chinese medicine for treating uremia as well as nephropathy syndrome and renal atrophy. The Chinese medicine is prepared with 50 kinds of Chinese medicinal materials, including coix seed, licorice, tree peony bark, ledebouriella root, shunk bugbane, etc. It can activate kidney tissue, stretch kidney and improve and restore kidney function to cure the said diseases radically.

A yeast in the form of micro capsule for controlling the release of protein medicine to treat uremia, hepatal failure, phenylketonuria, cancer, etc has the sodium alginate-chitosan-sodium alginate structure, and the yeast is dispersed proportionally in the liquid contained in the micro capsule.

The invention discloses an application of French marigold general flavone extract in the preparation of anti-prostatitis drugs. A preparation method of the French marigold general flavone extract comprises the following steps: 1, extracting French marigold by an ethanol-water solution at least one time to obtain an extract liquid, and concentrating the extract liquid to obtain a concentrate; 2, degreasing the concentrate by a degreasing solvent to obtain a degreased concentrate; and 3, separating and purifying the degreased concentrate to obtain the French marigold general flavone extract. The weight content of general flavones in the French marigold general flavone extract, detected through colourimetry, is higher than 30%. Pharmacological test proves that the French marigold general flavone extract has high anti-prostatitis activity, and can be applied to preparations of the anti-prostatitis drugs individually or after being combined with other drugs. The purity of the general flavones in the French marigold general flavone extract prepared through the method is high, and the preparation method is simple, so the extract is suitable for industrial production; and the French marigold general flavone extract can be used for preparing the anti-prostatitis drugs.

The invention relates to a construction method of a uremia peripheral blood mononuclear cell long-chain non-coding ribonucleic acid difference expression spectrum model, which comprises the following steps of: A1, obtaining the in vitro test peripheral blood samples of the uremia patient group and the normal control group and respectively obtaining gene chip data for each test peripheral blood sample; and A2, uploading the gene chip data of each test peripheral blood sample to gene chip data analysis software, setting the normalized standard and data filtering ratio times, obtaining the difference expression gene and obtaining the uremia peripheral blood mononuclear cell long-chain non-coding ribonucleic acid difference expression spectrum model. Through the scheme, the information as themiddle results is provided for the study on the uremia, and in addition, a novel idea is provided for further disclosing the pathological mechanism of the uremia. In addition, the invention also relates to the uremia peripheral blood mononuclear cell long-chain non-coding ribonucleic acid difference expression spectrum model.

The invention discloses a Chinese medicinal composition for treating uremia and a preparation method thereof. The Chinese medicinal composition for treating the uremia comprises the following raw materials by weight: 30 grams of coix seed, 20 grams of achyranthes root, 10 grams of wrinkled gianthyssop herb, 10 grams of officinal magnolia bark, 10 grams of pinellia tuber, 20 grams of poria, 10 grams of bamboo shavings, 20 grams of stir-fried largehead atractylodes rhizome, 30 grams of astragalus, 20 grams of tangerine peel, 20 grams of scorch-fried malt, 20 grams of scorch-fried hawthorn fruit, 20 grams of scorch-fried medicated leaven, 20 grams of stir-fried chicken's gizzard-membrane, 20 grams of morning glory seed, 20 grams of rhubarb, 30 grams of raw oyster shell powder, 20 grams of agaric, 20 grams of plantain seed, 20 grams of oriental waterplantain rhizome, 50 grams of motherwort herb, 20 grams of pyrrosia leaf and the like. The Chinese medicinal composition is prepared into decoction or concentrated pills or concentrated capsules by the conventional method, and can be used for treating the uremia.

The invention discloses a Chinese medicine used for curing uremia, which is invented for solving the defect that treatment effect of the prior art has a great toxic and side effects. The Chinese medicine is prepared by raw materials comprising 20g of parched Chinese atractylodes rhizome, 20g of amur corktree bark, 30g of coix seed kernels, 20g of radix achyranthis bidentatae, 10g of agastache, 10g of officinal magnolia bark, 10g of pinellia tuber, 20g of poria, 20g of parched white atractylodes rhizome, 20g of astragalus roots, 20g of caramel malt, 20g of parched hawthorn fruit, 20g of stir-baked massa fermentata medici-nalis, 20g of tangerine pee, 10g of semen pharbitidis, 15g of rhubarb, 30g of crude ostreae testa pulverata, 10g of polyporus umbellatus and 10g of rhizoma alismatis; wherein, the Chiese atractylodes rhizome, the amur corktree bark, the radix achyranthis bidentatae and the coix seed kernels are used for clearing away heat and promoting diuresis; the agastache, the officinal magnolia bark, the pinellia tuber, the poria, the parched white atractylodes rhizome and the tangerine pee are used for cleaning middle warmer water-wet pathogen and also have effect of strengthening the spleen; the astragalus roots are beneficial for vital energy, invigorating splenic yang and inducing diuresis to alleviate edema; the charred triplet promotes digestion, medicine and absorption; the semen pharbitidis, the rhubarb, crude ostreae testa pulverata, the polyporus umbellatus and the rhizoma alismatis alleviate water retention, eliminate toxicant and remove pathogen. Symptoms are improved until healing when pathogen is removed and healthy energy is recovered.

A method as well as an apparatus is disclosed for determining the efficiency of a currently performed kidney replacement therapy on the dialysis side making use of a dialysis machine which in a first step is operated in a hemodialysis or hemodiafiltration process and in a second step is sequentially changed over to a hemofiltration process or is changed over to a sequential mode in which merely a flow from the blood compartment via the semipermeable membrane to the dialysis fluid compartment of the dialyser is generated in which, according to a third step, a sensor for determining or measuring the concentration at least of uremic toxins in the saturated dialysate or ultra-filtrate which is connected downstream of a dialyser on the dialysis side outputs corresponding measuring signals that are representative of the current concentration at least of uremic toxins in the blood to a calculation or determination unit.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of CFB, C9 and/or C3 and to treat subjects having a complement component-associated disease, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

The invention discloses a traditional Chinese medicine composition for treating pruritus cutanea after hematodialysis. The pruritus cutanea after hematodialysis is caused by damp according to traditional Chinese medicine; the pruritus cutanea of uremia is mainly caused by blood-insufficiency damp, the damp toxin is accumulated in striae and interstitial space and causes that the skin is not moistened and nourished. The traditional Chinese medicine composition is characterized in that the traditional Chinese medicines capable of eliminating dampness and detoxifying, promoting circulation and removing stasis, and warmly invigorating kidney Yang are innovatively selected, including hairy grape stem, glandular showy himalayahoneysuckle herb, laxflower pottsia root, evans begonia root, convallaria majalis, ventilago leiocarpa benth, berb of wusheng clematis, agastache rugosus and shrubby cordyline flower. The clinical test shows that the curing rate and the total effective rate of the treatment group respectively reach 40.0% and 80.0%, which are obviously superior to those of the control group.

A Chinese medicine in the form of ointment for treating uremia, renal hypertension and hyperlipomia is prepared from 20 Chinese-medicinal materials including Chinese rhubarb, forsythia fruit, Dragon's bone, red sage root, honeysuckle flower, etc. Its advantages are high effective rate (more than 98%), quickly and durably taking its effect, no recurrence and low cost.

The invention relates to a preparation method of a western blot polymeric adsorbent and an adsorption device. The preparation method comprises the following steps: step 1, siloxane monomers are mixedand uniformly dispersed under the conditions of nitrogen atmosphere and temperature lower than normal temperature; step 2, polymeric microspheres are subjected to amination and aldehyde treatment, anda pore forming agent is loaded; step 3, a protein aqueous solution and a mixture obtained in step 2 are uniformly dispersed in the mixture obtained in step 1, acid is added, and a condensation reaction is performed; step 4, the mixture obtained in step 3 is filtered, a product is washed to be neutral and dried, and the western blot polymeric adsorbent is prepared. The preparation method is simpleto operate, and the obtained western blot polymeric adsorbent is high in toxin adsorption rate and is particularly suitable for hemoperfusion of uremia.

The invention belongs to the field of a medicine preparation, and particularly relates to a compound electrolyte glucose injection and a preparation method thereof. The injection is prepared from the following ingredients in parts by weight: 2.5 to 5.5g of sodium chloride, 0.1 to 0.4g of magnesium chloride, 0.1 to 0.3g of calcium chloride, 1 to 3g of sodium acetate, 0.25 to 0.75g of L-malic acid, 20 to 30g of glucose, 4.5 to 6.5g of pH regulators, 10 to 100mg of antioxidizers and injection water for reaching the total volume of 1000ml. The invention also provides a preparation process of the sterile injection. The injection prepared by the method is colorless and clear; the side reactions are few; the medication adaptability and the safety of patients are high; the injection is applicable to supplementation of water, electrolyte and carbohydrate after the operation or injury, and is particularly applicable to the patients with low immunity and the patients with diseases of hyperammonemia, angiocardiopathy, anemia, uremia, hypertension, burn wound and the like.

A immunity toxin expelling powder for treating uremia comprises (by weight ratio) astragalus root 5-10 parts, Chinese angelica root 1-3 parts, white atractylodes rhizome 1-3 parts, root of red rooted saliva 2-6 parts, corinth pink 1-3 parts, rheum officinale 10-20 parts, and the preparation process comprises comminuting, mixing, adding edible vinegar, stirring, and heating. The powder can increase the body's immunity function, improve kidney pathology and improve kidney's toxin expelling capacity.